Co-Diagnostics, Inc. (CODX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 162,910 | 50,277 | 641,141 | 2,656,840 |
| Cost of revenue | 32,106 | 21,590 | 297,403 | 212,148 |
| Gross profit | 130,804 | 28,687 | 343,738 | 2,444,692 |
| Sales and marketing | 609,713 | 657,030 | 1,059,745 | 1,041,243 |
| Research and development | 4,687,459 | 4,870,019 | 4,880,315 | 5,612,691 |
| General and administrative | 2,599,982 | 2,773,149 | 4,287,380 | 3,132,385 |
| Depreciation and amortization | 291,414 | 280,445 | 351,235 | 338,335 |
| Total operating expenses | 8,188,568 | 8,580,643 | 10,578,675 | 10,124,654 |
| Loss from operations | -8,057,764 | -8,551,956 | -10,234,937 | -7,679,962 |
| Gain on remeasurement of acquisition contingencies | - | 717,067 | - | - |
| Realized gain on investments | 340,358 | 301,465 | 293,067 | 74,165 |
| Interest income, net | 12,158 | 13,601 | 263,335 | 342,188 |
| Loss on equity method investment in joint venture | -13,760 | -1,444 | 12,683 | -74,503 |
| Gain (loss) on disposition of assets | -9,004 | - | 3,513 | 3,500 |
| Gain (loss) on remeasurement of acquisition contingencies | 10,222 | - | -11,927 | -244,116 |
| Total other income, net | 339,974 | 1,030,689 | 560,671 | 101,234 |
| Loss before income taxes | -7,717,790 | -7,521,267 | -9,674,266 | -7,578,728 |
| Income tax provision | 12,327 | 12,004 | 22,189 | 20,590 |
| Net loss | -7,730,117 | -7,533,271 | -9,696,455 | -7,599,318 |
| Change in net unrealized gains (losses) on marketable securities, net of tax | -196,585 | -87,790 | 37,158 | 144,653 |
| Total other comprehensive income (loss) | -196,585 | -87,790 | 37,158 | 144,653 |
| Comprehensive loss | -7,926,702 | -7,621,061 | -9,659,297 | -7,454,665 |
| Basic | -0.23 | -0.24 | -0.32 | -0.25 |
| Basic | 33,108,399 | 32,048,953 | 30,494,206 | 30,124,696 |
| Diluted | -0.23 | -0.24 | -0.32 | -0.25 |
| Diluted | 33,108,399 | 32,048,953 | 30,494,206 | 30,124,696 |